Dr. Qing-Qing Ding, MD

Dr. Ding practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Ding's NPI, 1043507288, was assigned on July 8, 2011. Dr. Ding graduated from Tongji Medical University in 1995. Dr. Ding holds Texas license R1520.

Dr. Ding's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Ding's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ding practices. Vendor and product names are available with a free account.

Anatomic pathology and clinical pathology is Dr. Ding's primary specialty in the NPI Registry, under taxonomy code 207ZP0102X. Dr. Ding is board certified in pathology - anatomic/pathology - clinical by the American Board of Pathology. Dmand AI has Dr. Ding's licenses on file in 3 states: Texas, Pennsylvania and Missouri.

CMS data shows 764 Medicare services from Dr. Ding across 8 procedure codes in 2024, for 263 Medicare patients. Medicare paid $28,478 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 263 Medicare patients who saw Dr. Ding in 2024. The largest group is 65 to 74, with 143 patients. 75% of them have cancer, and 73% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.36, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ding's median patient age at 56, with 99% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Ding for performance year 2024, reported as part of a group. Dr. Ding accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 6 papers to Dr. Ding, published from 2013 to 2024. 2020 was the busiest year, with 2. The most frequent topics are Biomarkers, Tumor, Breast Neoplasms and Immunohistochemistry. Dr. Ding's most frequent co-authors are Hui Chen, MD, PhD, Gabriel N. Hortobagyi, MD and Lei Huo, MD.

CMS Open Payments shows 1 general payment to Dr. Ding from 1 drug or device company in 2022. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $86.

Dr. Ding graduated from Tongji Medical University in 1995.

Dr. Ding is in network with 14 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.